Population-based estimates of hepatitis E virus associated mortality in 1

- **Bangladesh** 2
- 3
- Repon C Paul^{1,2}, Heather F Gidding^{3,4}, Arifa Nazneen¹, Kajal C Banik¹, Shariful Amin Sumon¹, 4
- Kishor K Paul^{1,3}, Arifa Akram⁵, M Salim Uzzaman⁵, Alexandra Tejada-Strop⁶, Saleem Kamili⁶, 5
- Stephen P Luby⁷, Andrew Hayen⁸, Emily S Gurley⁹ 6
- 7
- 8 ¹icddr,b, Dhaka, Bangladesh
- 9 ²National Perinatal Epidemiology and Statistics Unit and Centre for Big Data Research in Health,
- 10 Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia
- 11 ³School of Population Health, Faculty of Medicine and Health, University of New South Wales,
- 12 Sydney, NSW, Australia
- 13 ⁴Health and Clinical Analytics Lab, Sydney School of Public Health Faculty of Medicine and
- 14 Health, University of Sydney
- ⁵Institute of Epidemiology, Disease Control and Research, Bangladesh 15
- ⁶Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia 16
- 17 ⁷Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California, United
- States of America 18
- ⁸School of Public Health, University of Technology Sydney, Sydney, Australia 19
- ^{1,9}Johns Hopkins Bloomberg School of Public Health, Baltimore, USA 20
- 21
- 22
- 23
- 24
- 25 Funding: The Centers for Disease Control and Prevention (CDC), United States
- 26
- 27 Word Count: Abstract: 246; Manuscript: 3,487; Table: 4; Map:1; Appendix:2

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 Abstract

- 29 Background
- 30 Hepatitis E virus (HEV) is endemic in many resource-poor countries. Despite an available
- 31 vaccine, data on HEV-associated mortality are scarce, hindering informed decisions. This study
- 32 aims to estimate the population-based rate of HEV-specific mortality in Bangladesh.
- 33 Methods
- 34 During December 2014-September 2017, we conducted surveillance in six tertiary hospitals in
- Bangladesh. Patients aged ≥14 years with acute jaundice were recruited, tested for IgM anti-
- 36 HEV, and followed up post-discharge. A mortality survey in the hospital catchment areas
- 37 identified deaths associated with acute jaundice, including maternal, stillbirths and neonatal
- 38 deaths delivered by a mother with acute jaundice during pregnancy, confirmed by two
- 39 independent physicians reviewing verbal autopsy data.
- 40 Findings
- 41 Out of 1,925 patients with acute jaundice identified and enrolled in the surveillance hospitals,
- 42 302 died, with 28 (9%) testing positive for IgM anti-HEV. In the hospital catchment areas, the
- 43 team identified 587 jaundice-associated deaths, including 25 maternal deaths. Combining
- 44 hospital-based surveillance and mortality survey data, the study estimated 986 (95% CI: 599-
- 45 1338) HEV-associated deaths annually among individuals aged \geq 14 years in Bangladesh,
- 46 including 163 (95% CI: 57-395) maternal deaths. Additionally, 279 (95% CI: 101-664) stillbirths
- 47 and 780 (95% CI: 365-1,297) neonatal deaths were attributed to HEV infection annually.
- 48 Interpretation
- 49 Prior Global Burden of Disease studies presented wildly varying modeling estimates of HEV-
- associated annual deaths, ranging from 50,000 in 2013 to 1,932 in 2019. This study is the first to
- 51 directly measure population-based estimates of mortality in Bangladesh, which can be used to
- 52 determine the cost-effectiveness of hepatitis E vaccination and other interventions.

53 Introduction

54 Hepatitis E virus (HEV) causes acute liver infection; transmission of genotypes 1 and 2 occurs among humans through the fecal-oral route, while genotypes 3 and 4 are zoonotic and primarily 55 infect humans through the consumption of undercooked meat^{1,2}. In low- and middle-income 56 countries, where fecal contamination of drinking water is common, genotypes 1 and 2 pose 57 significant public health concerns^{1,2}. In these settings, where HEV infection is a leading cause of 58 acute viral hepatitis¹, population-based studies estimating the disease burden are scarce due to 59 inadequate surveillance systems and limited vital registration of cause-specific deaths. 60 Existing estimates of the burden of HEV infection rely on mathematical models, including the 61

62 Global Burden of Disease effortwere built upon several strong assumptions^{3,4}. These

63 assumptions include predicting the proportion of people with antibodies against HEV who

64 develop clinical disease, comparing HEV-associated mortality between HEV endemic low- and

65 middle-income countries and high-income countries with effective vital registration, and

66 extrapolating the likelihood of death among hospitalized hepatitis E patients to non-hospitalized

67 severe cases. Notably, the global annual HEV-related death toll projections by these models

have varied significantly, from 70,000 in 2005 to 1,932 in 2019^{3-7} .

HEV infection is preventable through sanitation, adherence to safe food and water precautions, and potentially vaccination. Two hepatitis E vaccine candidates, following non-human primate experiments, progressed to clinical trials in humans^{8,9}. One of these vaccines, HEV 239, was licensed in China in 2011 and in Pakistan in 2020 for use among residents aged ≥16 years¹⁰. A major barrier to recommending the vaccine in routine national vaccination programs in other countries, however, is the lack of confidence in the wide-ranging burden of disease estimates and a dearth of population-based measurements of HEV-associated mortality¹¹.

During 2014-2017, the International Centre for Diarrhoeal Disease Research, Bangladesh
(icddr,b) in collaboration with the Institute of Epidemiology, Disease Research and Control
(IEDCR) of the Government of Bangladesh and the Centers for Disease Control and Prevention
(CDC), United States conducted a hospital-based acute jaundice surveillance study in Bangladesh
to identify patients admitted with acute jaundice¹². However, estimating morality burden from
hospital-based studies may not fully represent the general population due to healthcare access
disparities in many low- and middle-income countries¹³. We conducted a mortality survey in the

- 83 catchment areas of surveillance hospitals and calculated population-based estimates of HEV-
- 84 specific mortality by combining data from the hospital-based surveillance and mortality survey.

85 Methods

86 Hospital-based acute jaundice surveillance

- 87 Detailed information on hospital-based acute jaundice surveillance is available elsewhere¹². In
- 88 summary, a study spanning December 2014 to September 2017 investigated acute jaundice in
- 89 six randomly selected tertiary hospitals across five divisions in Bangladesh (Figure 1). Patients
- 90 aged ≥14 years, exhibiting acute jaundice (defined as new onset of yellow sclera or skin during
- 91 the past 3 months, persisting on admission day), were recruited. Blood samples from all
- 92 recruited patients were tested for IgM anti-HEV using an enzyme-linked immunosorbent assay
- 93 (ELISA) with a sensitivity of 98-100% and a specificity of 95-100% (Beijing Wantai Biologic
- 94 Pharmacy Enterprise Co., Ltd, Beijing, China). Patients positive for IgM anti-HEV antibodies were
- 95 considered to have acute HEV infection.
- 96 Enrolled patients were followed during their hospitalization and for 3 months post-discharge to
- 97 ascertain vital status and pregnancy outcomes for pregnant women. However, post-discharge
- 98 follow-up was not possible for patients admitted after June, 2017, as surveillance ended on
- 99 September 30, 2017.

100 Mortality survey in hospital catchment areas

101 Selection of hospital catchment areas

- 102 The study team reviewed the hospital records of jaundice patients admitted from January to
- 103 June 2014 to identify the primary catchment areas of each surveillance hospital, defined as the
- sub-districts where 75% of the admitted jaundice patients resided. Applying this criterion, we
- selected 63 sub-districts accorss 18 districts (out of 64) in Bangladesh. Sub-districts in
- 106 Bangladesh consist of a median of 15 unions (IQR: 7-20 unions), which are the smallest
- administrative units in Bangladesh with an average population of 26,000 people¹⁴.

108 Selection of survey clusters

109 For rare events, such as maternal deaths, a large sample size is required to estimate death rates 110 with acceptable precision¹⁵. Therefore, we assumed that our study, designed to estimate 111 maternal mortality associated with HEV infection with acceptable precision, would also provide 112 sufficient power for estimating mortality in adults, neonatal deaths, and stillbirths associated with HEV infection. The sample size for estimating maternal mortality was determined using the 113 formula for estimating proportions¹⁶, assuming that 10% of maternal deaths are associated with 114 HEV infection¹⁷. With a precision of 5%, a 95% confidence level, and a design effect of 2.0, we 115 116 calculated a required sample size of 277 maternal deaths in the surveillance hospitals' catchment areas. To achieve this size, we conducted the survey in 91 unions, collecting 117 118 mortality data for the prior three years. Assuming a maternal mortality ratio of 194 per 100,000 live births¹⁸ and the crude live birth rate of 22.2 per 1,000 population¹⁹, we randomly selected 119 120 91 unions from the defined hospital catchment areas using a probability proportional to size 121 sampling approach²⁰.

122 Mortality Survey

123 Between November 2014 and February 2017, a mortality survey was undertaken across 91 124 unions to identify deaths associated with jaundice. The survey also identified stillborn babies 125 and live-born babies who died during neonatal period delivered by mothers with jaundice 126 during pregnancy, and all-cause maternal deaths (Figure 1). Jaundice was defined as having new 127 onset of either yellow sclera or skin during the illness prior to death. A neonatal death was 128 defined as occuring within the first 28 days of life, while a stillbirth was defined as a baby delivered by a mother after 28 weeks of gestation with no signs of life²¹. Maternal death was 129 130 defined as the death of a woman while pregnant or within 42 days of pregnancy termination, 131 excluding unintentional injuries or unrelated incidental causes²¹.

In urban communities, we conducted a house-to-house survey to identify deaths, whereas in
rural communities, we used a low-cost community knowledge approach (further detailed in²²).
Out of 91 unions, 25 (27%) were urban, closely matching the urban population percentage
(23%) in the 2011 Bangladesh Population Census²³. For identified jaundice-associated deaths
and all-cause maternal deaths, a verbal autopsy questionnaire was administered to collect
detailed information on the signs, symptoms and duration of illness preceding death to
determine the underlying and immediate cause of death. Two physicians independently

assessed VA questionnaires, assigning ICD-10 cause of death codes. Discordant cases prompted
 discussion for consensus, with a third physician intervening if disagreement persisted.

141 Data analysis

142 We calculated the HEV-associated mortality rate for individuals aged ≥14 years, maternal 143 mortality ratio, and stillbirth and neonatal mortality rate for all catchment areas combined. The population in 2014 served as our mid-year reference, considering our data collection spanned 144 from November 2014 and February 2017 (about 60% collected in 2015) and we collected 145 146 mortality data for the prior three years. For rural unions, we projected the population for 2014 147 based on the 2011 Bangladesh census, considering an annual growth rate of 1.37% (Appendix 148 1)²⁴. For the urban unions, we counted the household population at the time of mortality 149 survey. We projected the population aged ≥ 14 years, assuming 67.7% of total population in 2014 were aged \geq 14 years²⁴. The number of live births in 2014 was estimated assuming a crude 150 birth rate of 22.2 per 1,000 population as per the Bangladesh Demographic and Health Survey, 151 2014¹⁹. 152

153 Although we collected information on both chronic and acute jaundice associated deaths in the 154 mortality survey, for incidence calculation only deaths associated with acute jaundice were 155 considered, defined as new onset of yellow eyes or skin within the 3 months prior to death. 156 Because we used the same case definition of acute jaundice in hospitals and hospital catchment 157 areas, we assumed that the illness in people who died in the catchment areas was similar to those who died in the study hospitals. To calculate HEV associated mortality in the hospital 158 catchment areas, we multiplied the estimate for jaundice-associated mortality in the hospital 159 catchment areas by the proportion of HEV infections among acute jaundice deaths in the 160 161 surveillance hospitals.

162 Recognizing HEV's additional risk during pregnancy^{1,2} and its varying age-specific infection rates 163 and severity²⁵, we separately projected HEV-associated deaths among pregnant women and 164 non-pregnant persons aged \geq 14 years (14-44 years, 45-59 years, and \geq 60 years). The projected 165 deaths in both groups were aggregated to estimate the total number of HEV-associated deaths 166 in the hospital catchment areas. We used the following equation to estimate mortality 167 associated with HEV in the hospital catchment areas:

168 HEV associated mortality for the population aged ≥14 years =

perpetuity. All rights reserved. No reuse allowed without permission.

169

$$\frac{D_m \frac{E_m}{J_m} + \sum D_i \frac{E_i}{J_i}}{P * 3} \times 100,000$$

170 where,

- 171 P = Estimated population aged \geq 14 years in the study areas in 2014
- 172 D_m =Number of maternal deaths associated with acute jaundice identified in the three-year
- 173 period in the study areas
- 174 J_m = Number of maternal deaths associated with acute jaundice in the surveillance hospitals
- 175 E_m = Number of laboratory-confirmed HEV cases among maternal deaths associated with acute
- 176 jaundice in the surveillance hospitals
- 177 D_i = Number of age-specific non-maternal deaths associated with acute jaundice identified in
- 178 the three-year period in the study areas
- 179 J_i = Number of age-specific non-maternal deaths associated with acute jaundice in the
- 180 surveillance hospitals
- 181 E_i = Number of age-specific laboratory-confirmed HEV cases among non-maternal deaths
- 182 associated with acute jaundice in the surveillance hospitals

- 184 Similarly, the following formulas were used to calculate HEV associated maternal mortality,
- 185 neonatal mortality and stillbirth:
- 186 Maternal mortality ratio associated with HEV = $\left(\frac{D_m/3}{B}\right)\left(\frac{E_m}{J_m}\right) \times 100,000$
- 187 Stillbirth rate associated with HEV = $\binom{S_{3}}{B} \binom{S_{e}}{S_{j}} \times 100,000$
- 188 Neonatal mortality rate associated with HEV = $\left(\frac{N_{3}}{B}\right)\left(\frac{N_{e}}{N_{j}}\right) \times 100,000$
- 189 where, D_m , J_m and E_m are defined above and:
- 190 B = Estimated live births in the study areas in 2014
- 191 S = Number of stillbirths delivered by a mother with acute jaundice during pregnancy
- 192 identified in the three-year period in the study areas

- 193 S_i = Number of stillbirths delivered by a mother with acute jaundice during pregnancy in the
- 194 surveillance hospitals
- 195 S_e = Number of stillbirths delivered by a mother with acute HEV during pregnancy in the
- 196 surveillance hospitals
- 197 N = Number of neonatal deaths born to a mother with acute jaundice during pregnancy
- 198 identified in the three-year period in the study areas
- 199 N_j = Number of neonatal deaths born to a mother with acute jaundice during pregnancy in the 200 surveillance hospitals
- 201 N_e = Number of neonatal deaths born to a mother with acute HEV during pregnancy in the
- 202 surveillance hospitals
- 203

204 We used non-parametric bootstrapping²⁶ to estimate the 95% confidence intervals for hepatitis 205 E associated mortality for the population aged ≥14 years. The 95% confidence intervals for 206 maternal mortality, stillbirth and neonatal mortality associated with HEV infection were 207 calculated by multiplying the lower and upper bounds of the jaundice associated mortality in 208 the hospital catchment areas by the respective lower and upper bounds of the proportion of 209 HEV infection among acute jaundice deaths in the study hospitals. The 95% confidence interval 210 of the proportion of hepatitis E among acute jaundice deaths in the study hospitals was 211 calculated by using the Wilson method for a binomial distribution²⁷, and the 95% confidence 212 interval for jaundice associated deaths in the hospital catchment areas was calculated using the 213 confidence interval for the mean of a Poisson distribution. We performed a sensitivity analysis 214 to check how the estimates of HEV-associated mortality vary when restricted to a two-year and 215 one-year recall period.

216 **Population mortality estimates**

The hepatitis E-associated mortality estimates generated from the study hospitals and the mortality surveys in the hospital catchment areas were considered representative of the hospital catchment areas, and with surveillance hospitals covering 5 out of 7 administrative divisions, we expected that results could be extrapolated to the whole country (Figure 1). The rural to urban population ratio of our study matched the national ratio, which was important

because urbanicity is a known risk factor for HEV infection²³. We, therefore, used our morality
estimates to extrapolate the total number of HEV-associated deaths among the population aged
≥14 years, maternal deaths associated with HEV, stillborn babies and live born babies who died
during the neonatal period delivered by mothers with acute HEV infection in pregnancy in 2014
in Bangladesh.

227 Ethical approval and consent

The study protocol was reviewed and approved by the institutional review board of the icddr,b (Protocol # PR-14060). In the surveillance hospitals, written informed consent was obtained from patients over 17 years. For patients aged 14-17 years, assent was taken from the patients and written consent from their parents. Written consent was sought from their guardians or accompanying attendants if the patients were unable to provide consent themselves because of illness. In the mortality survey in the hospital catchment areas, written consent was obtained from a family member of the deceased directly involved in caregiving during the illness period.

235 **Results**

236 Deaths among hospitalized acute jaundice patients

237 In the six study hospitals, 1,925 acute jaundice patients were identified during December 2014

to September 2017; all patients consented for enrolment. Of them, 1,765 patients (92%;

239 including 173 pregnant women) were followed-up during hospitalization and three months

post-discharge. Among these patients, 302 died (17%), including 27 maternal deaths, and 28 of

these deaths (9%; 95% CI: 6%-13%) tested positive for IgM anti-HEV. Among the maternal

deaths, 8 cases (30%; 95% CI: 16%-49%) were positive for IgM anti-HEV (Table 1).

Among the 173 pregnant women followed, 125 (72%) had live births, 27 (16%) experienced

stillbirths, 11 (6%) had miscarriages, and 10 (6%) women died before the pregnancy outcome.

Of the enrolled pregnant women, 66 (38%) tested positive for IgM anti-HEV. Six (22%; 95% CI:

246 11%-41%) of the 27 stillbirths were delivered by mothers with IgM anti-HEV positivity. Among

the live births, 15 (12%) died within 28 days of their birth (neonatal deaths). Ten (67%; 95% CI:

248 42%-85%) of the 15 neonatal deaths were born to mothers who were positive for IgM anti-HEV.

Acute jaundice deaths in the hospital catchment areas

- 250 In the catchment areas of study hospitals, the team identified 33,794 deaths among persons
- aged ≥14 years who died in the three years prior to the date of survey (Table 2). Among these,
- 252 277 (0.8%) were maternal deaths. Of the maternal deaths, 25 (9%) had acute jaundice, and of
- the non-maternal deaths, 587 (1.7%) had acute jaundice prior to death. There were 57 stillbirths
- and 53 neonatal deaths delivered by mothers with acute jaundice during pregnancy identified.

255 **Demographic characteristics of acute jaundice deaths**

- 256 *Surveillance hospitals:* Among non-maternal acute jaundice deaths, about two-thirds were
- 257 males, and one-third were aged ≥60 years (Table 3). Eighty-two percent resided in rural areas,
- and 40% did no formal education. In most cases (72%), jaundice duration before hospitalization
- 259 was less than one month, and over three-quarters of the deaths occurred at home post-
- 260 discharge.
- 261 *Hospital catchment areas:* The sex ratio of acute jaundice deaths identified in the hospital
- 262 catchment areas was similar to those in the surveillance hospitals (p=0.288) (Table 3). However,
- the patients who died in the hospital catchment areas were older than the patients who died
- after enrolment in the hospital surveillance study (p <0.001).

265 **Population-based estimate of HEV associated mortality**

- 266 In the 91 unions selected from the catchment areas of six study hospitals, the projected
- 267 population aged ≥14 years was approximately 1.6 million, and the projected number of live
- births was 52,326 in 2014 (Appendix 1). We estimated HEV-associated mortality as 0.9 (95% CI:
- 269 0.6-1.3) per 100,000 population aged ≥14 years (Table 4). The maternal mortality ratio
- associated with HEV was estimated as 4.7 (95% CI: 1.6-11.4) per 100,000 live births. We
- estimated the HEV associated stillbirth rate as 8.1 (95% CI: 2.9-19.2) and neonatal mortality rate
- as 22.5 (95% CI: 10.5-34.5) per 100,000 live births. We extrapolated these estimates to the
- whole population of Bangladesh and estimated that in 2014 there were 986 (95% CI: 599-1338)
- HEV-associated deaths among the population aged ≥14 years including 163 (95% CI: 57-395)
- 275 maternal deaths. Additionally, we estimated 279 (95% CI: 101-664) stillbirths and 780 (95% CI:
- 276 365-1,297) neonatal deaths associated with HEV infection in 2014 in Bangladesh.

In the sensitivity analysis for a two-year recall period, the estimated annual number of HEVassociated deaths were 1,114 (95% CI: 634-1,584) for population aged ≥14 years (including 186
(95% CI: 60-476) maternal deaths), 375 (95% CI: 133-904) stillbirths and 780 (95% CI: 337-1,367)
neonatal deaths (Appendix 2). For one year recall period, the estimated number of HEVassociated annual deaths were 1,101 (95% CI: 422-1,901) for population aged ≥14 years
(including 177 (95% CI: 43-548) maternal deaths), 412 (95% CI: 131-1092) stillbirths and 927
(95% CI: 359-1802) neonatal deaths.

284 **Discussion**

285 This study provides the first measured estimate of HEV associated mortality in Bangladesh by 286 combining data from a mortality survey covering a population of over 2.3 million and hospital-287 based acute jaundice surveillance in six hospitals across the country. In the absence of any reported HEV outbreak in Bangladesh during 2013-2015, we estimated that HEV infection 288 289 accounted for 1766 (95% CI: 964-2635) deaths annually, including pregnant women and neonates. Additionally, we estimated 279 stillbirths per year, which are excluded from global 290 291 burden of disease estimates⁷, despite their significant physical and psychological toll. Preventing 292 HEV infections during pregnancy could prevent an estimated 1,222 maternal and neonatal 293 deaths and stillbirths annually. This population-based estimate of HEV mortality in Bangladesh 294 can inform the cost-effectiveness of HEV vaccination and other control measures to help 295 prioritise public health interventions.

296 The Global Burden of Disease (GBD) studies provide estimates of global and country-level 297 disease burdens, including hepatitis E, by employing models based on available data from vital 298 registration, surveillance, and verbal autopsy⁷. Most recently, the 2019 GBD study estimated that 299 there were 1,932 HEV-associated deaths globally in 2019⁷, which appears to be a significant 300 underestimate as we identified approximately this many deaths in Bangladesh alone. The HEV mortality estimate by GBD studies appears to be sharp reduction, from 70,000 in 2005, 50,000 in 301 2013, 26,100 in 2016 and 14,700 in 2017³⁻⁶. This sudden decrease is likely due to methodological 302 303 changes in calculation and the use of different data sources across various GBD studies. For 304 instance, GBD studies transitioned from a single cause-of-death ensemble model (CODEm) to a 305 two-model hybrid approach in 2013, incorporating a global CODEm model and a CODEm model

limited to data-rich countries^{3,4,7}. Moreover, GBD 2019 considered location- and year-specific
 factors for virus-specific case fatality rates⁷.

The 2013 global burden of disease study estimated 38,738 viral hepatitis deaths (25 deaths/100,000 population) in Bangladesh, with 12.7% attributed to HEV, totalling 4,920 HEVassociated deaths⁴. However, subsequent GBD studies conducted in 2017 and 2019 reported significantly lower figures of 227 and 111 HEV-associated deaths, respectively^{6,7}. These variations and model uncertainties have left decision-makers hesitant on efficient vaccine implementation.

314 We note a number of study limitations. First, in the hospital catchment areas, the signs of 315 jaundice among deaths were not verified by medical professionals; instead, caregivers reported 316 symptoms of jaundice in decedents who had passed away within 3 years of the survey. Although our trained field team explained jaundice symptoms, and laypersons can identify eye yellowing 317 318 when pronounced, misclassification may have occurred. This limitation in common in mortality surveys using the verbal autopsy method. Second, conducting interviews with caregivers 319 promptly is crucial for accurate cause-of-death identification, as delays between death and the 320 survey may introduce bias in reported symptoms²⁸. Our sensitivity analysis showed slightly 321 lower number of identified jaundice-associated deaths in the third year preceding the survey 322 323 compared to the first two years. While uncertain if this reflects a true change in burden or 324 random fluctuation, we provided separate estimations for HEV-associated deaths based on the one and two years recall periods, illustrating how estimates vary when restricting recall bias 325 326 (Appendix 2). Third, while the Wantai IgM anti-HEV ELISA test is widely accepted as highly 327 sensitive for diagnosing acute HEV infections, a study by Huang et al. observed that about 3% of acute viral hepatitis cases were negative for IgM anti-HEV but had a 4-fold rise in IgG anti-HEV in 328 their convalescent sera, indicating potential underestimation in our prevalence estimates due to 329 330 the test's sensitivity²⁹. Fourth, our assessment of HEV mortality in Bangladesh did not account 331 for miscarriages, which is significant among pregnant women with HEV infection³⁰. Finally, this 332 study presents the HEV burden in Bangladesh based on data six to nine years old, which may not precisely reflect the current situation. Nonetheless, there are no other measured estimates of 333 334 HEV mortality in Bangladesh, so our estimates remain useful. Since there have been no targeted strategies to reduce HEV transmission since this study, it is unlikely that there has been a 335 336 significant change in HEV burden in Bangladesh over this period.

337 This study provides a dependable estimate of HEV associated mortality in Bangladesh in the 338 absence of reliable data on HEV associated mortality in Bangladesh or in any region of the 339 world¹¹. Data from this study highlight the substantial underestimates of HEV deaths globally, based on the latest global burden of disease estimates published in 2020⁷, suggesting that these 340 341 estimates should not be used for making decisions about global recommendations or policies. Our data from Bangladesh can help determine the cost-effectiveness of vaccination against HEV 342 343 and other interventions, including improvement of drinking water quality, for national 344 policymakers, and our methods can be used by other countries requiring accurate HEV-345 associated mortality estimates.

346

- 347 Disclaimer: The findings and conclusions in this report are those of the authors and do not
- 348 necessarily reflect the official position of the Centers for Disease Control and Prevention, or the
- 349 authors' affiliated institutions.


References 351

352	1. Aggarwal R, Jameel S. Hepatitis E. <i>Hepatology</i> 2011; 54 (6): 2218-26.
353	2. Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human
354	hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med 1980; 68(6): 818-24.
355	3. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E
356	virus genotypes 1 and 2 in 2005. <i>Hepatology</i> 2012; 55 (4): 988-97.
357	4. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to
358	2013: findings from the Global Burden of Disease Study 2013. The Lancet 2016; 388 (10049): 1081-8.
359	5. Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of
360	death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;
361	390 (10100): 1151-210.
362	6. Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of
363	death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease
364	Study 2017. Lancet 2018; 392 (10159): 1736-88.
365	7. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and
366	territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> 2020;
367	396 (10258): 1204-22.
368	8. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine.
369	N Engl J Med 2007; 356 (9): 895-903.
370	9. Li SW, Zhang J, Li YM, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity,
371	immunogenicity and protectivity on primates. Vaccine 2005; 23 (22): 2893-901.
372	10. World Health Organization. Hepatitis E vaccines background paper: Strategic Advisory Group of
373	Experts (SAGE) on Immunization meeting. 2024. [Cited June 14, 2024]. Available from: chrome-
373 374	extension://efaidnbmnnnibpcajpcglclefindmkaj/ <u>https://cdn.who.int/media/docs/default-</u>
375	source/immunization/sage/2024/march/hepatitis e background paper sage mar24.pdf?sfvrsn=e1443
376	8c4 1 2024.
377	11. World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization,
378	October 2014 – conclusions and recommendations. [Cited December 03, 2017]. Available from:
379	http://apps.who.int/iris/bitstream/handle/10665/242296/WER8950_561-
380	576.PDF?sequence=1&isAllowed=y.
381	12. Paul RC, Nazneen A, Banik KC, et al. Hepatitis E as a cause of adult hospitalization in Bangladesh:
382	Results from an acute jaundice surveillance study in six tertiary hospitals, 2014-2017. 2020; 14 (1):
383	e0007586.
384	13. Murray CJ, Lopez AD, Barofsky JT, Bryson-Cahn C, Lozano R. Estimating population cause-specific
385	mortality fractions from in-hospital mortality: validation of a new method. <i>PLoS Med</i> 2007; 4 (11): e326.
386	14. Bangladesh Bureau of Statistics. Bangladesh population and housing census 2011. [Cited May 18,
387	2024]. Available from: http://www.bbs.gov.bd/site/page/47856ad0-7e1c-4aab-bd78-
388	892733bc06eb/Population-and-Housing-Census.
389	15. Chow S-C, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research: CRC press;
390	2017.
390 391	
392	
	Sons 1991: 209-15.
393	17. Gurley ES, Halder AK, Streatfield PK, et al. Estimating the burden of maternal and neonatal
394	deaths associated with jaundice in Bangladesh: possible role of hepatitis E infection. Am J Public Health
395	2012; 102 (12): 2248-54.
396	18. National Institute of Population Research and Training (NIPORT), MEASURE Evaluation, ICDDRB.
397	Bangladesh maternal mortality and health care survey 2010. Dhaka, Bangladesh: NIPORT, MEASURE
398	Evaluation, and ICDDR, B. 2012. [Cited April 21, 2017]. Available from:
399	https://www.measureevaluation.org/resources/publications/tr-12-87.
400	19. National Institute of Population Research and Training (NIPORT), Mitra and Associates, ICF
401	International. Bangladesh Demographic and Health Survey 2014. Dhaka, Bangladesh, and Rockville,

All rights reserved. No reuse allowed without permission.

- Maryland, USA: NIPORT, Mitra and Associates, and ICF International. [Cited July 28, 2018]. Available
 from: <u>https://dhsprogram.com/pubs/pdf/FR311/FR311.pdf</u>, 2016.
- 404 20. Yates F, Grundy PM. Selection without replacement from within strata with probability
- 405 proportional to size. *Journal of the Royal Statistical Society Series B (Methodological)* 1953: 253-61.
- World Health Organization. International statistical classification of diseases and related health
 problems, tenth revision. Geneva: World Health Organization. 1992.
- Paul RC, Gidding HF, Nazneen A, et al. A Low-Cost, Community Knowledge Approach to Estimate
 Maternal and Jaundice-Associated Mortality in Rural Bangladesh. *Am J Trop Med Hyg* 2018; **99**(6): 16338.
- 411 23. Bangladesh Bureau of Statistics. Bangladesh population and housing census 2011- Urban area
 412 report. 2014. [Cited December 23, 2018]. Available from:
- 413 <u>http://203.112.218.65:8008/WebTestApplication/userfiles/Image/National%20Reports/Population%20%</u>
 414 <u>20Housing%20Census%202011.pdf</u>.
- 415 24. Bangladesh Bureau of Statistics. Sample vital registration system, 2013. [Cited July 02, 2017].416 Available from:
- 417 <u>http://203.112.218.65/WebTestApplication/userfiles/Image/LatestReports/MSVSB_Report_2013.pdf</u>.
- 418 25. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. *N Engl J Med* 2012; **367**(13): 1237-44.
- 419 26. Efron B, Tibshirani RJ. An introduction to the bootstrap: CRC press; 1994.
- 420 27. Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. *Statistical science*421 2001: 101-17.
- 422 28. Mirza NM, Macharia W, Wafula E, Agwanda R, Onyango F. Verbal autopsy: a tool for determining 423 cause of death in a community. *East Afr Med J* 1990; **67**(10): 693-8.
- 424 29. Huang S, Zhang X, Jiang H, et al. Profile of acute infectious markers in sporadic hepatitis E. *PLoS*425 *One* 2010; 5(10): e13560.
- 426 30. Heemelaar S, Hangula AL, Chipeio ML, et al. Maternal and fetal outcomes of pregnancies
- 427 complicated by acute hepatitis E and the impact of HIV status: A cross-sectional study in Namibia. *Liver*428 *Int* 2022; **42**(1): 50-8.

- Figure 1: Map of Bangladesh showing the acute jaundice surveillance sites and the selected 430
- areas (sub-districts) for mortality survey, December 2014- September 2017 431



432

Table 1: Hepatitis E cases among patients with acute jaundice who died during hospitalization 434

435 or within three months of hospital discharge in six tertiary hospitals in Bangladesh, December

2014–September 2017 436

Characteristics	Patients with acute jaundice _	lgM Anti-HEV Positive (N=28)		
	who died [*] (N=302)	n	Percent (95% Cl)	
Maternal deaths	27	8	29.6 (15.8-48.5)	
Non-maternal deaths	275	20	7.2 (4.8-11.0)	
Sex				
Male	178	13	7.3 (4.3-12.1)	
Female	97	7	7.2 (3.5-14.2)	
Age group				
14-44 years	96	14	14.6 (8.9-23.6)	
45-59 years	86	3	3.5 (1.2-9.8)	
60+ years	93	3	3.2 (1.1-9.1)	

437 438 * Defined as new onset of either yellow eyes or skin during the past 3 months, continuing on the day of admission.

- 439
- 440

441

442 Table 2: Deaths associated with acute jaundice in the catchment areas of the six surveillance

- 443 hospitals, Bangladesh during the three-year period prior to the survey (Survey period:
- November 2014–February 2017) 444

Characteristics	Dea aged ≥ 1	Total		
Characteristics	Maternal deaths	Non-maternal deaths	Total	
Deaths identified in the study areas*	277	33,517	33,794	
Deaths with jaundice † prior to death	28 (10.1%)	778 (2.3%)	806 (2.4%)	
	[95% CI: 7.0%-14.2%]	[95% CI: 2.2%-2.5%]	[95% CI: 2.2%-2.6%]	
Deaths with acute jaundice [¥] prior to death	25 (9.0%)	587 (1.7%)	612 (1.8%)	
	[95% CI: 6.1%-12.9%]	[95% CI: 1.6%-1.9%]	[95% CI: 1.7%-1.9%]	

445 * There were two more maternal deaths for whom their caregivers refused to participate in this study.

446 + Defined as having yellow eyes or skin prior to death

447 ¥ Defined as new onset of either yellow eyes or skin during the 3 months prior to death

- 449 Table 3: Demographic characteristics of enrolled patients with acute jaundice in the study
- 450 hospitals who died during hospitalization or within three months of hospital discharge and
- 451 identified deaths associated with acute jaundice in the hospital catchment areas during the
- 452 three-year period prior to the survey

	Dea	ths* in hospi	tals	Deaths*	in hospital ca areas	itchment	
	Maternal	Non- maternal	Total	Maternal	Non- maternal	Total N=612	
Characteristics	N=27 n (%)	N=275 n (%)	N=302 n (%)	N=25 n (%)	N=587 n (%)	n (%)	P-value†
Sex	(0.288
Male	-	178 (65)	178 (59)	-	383 (65)	383 (63)	
Female	27 (100)	97 (35)	124 (41)	25 (100)	204 (35)	229 (37)	
Age in years							<0.001
14-44	27 (100)	96 (35)	123 (41)	25 (100)	158 (27)	183 (30)	
45-59	0	86 (31)	86 (29)	0	160 (27)	160 (26)	
≥ 60	0	93 (34)	93 (31)	0	269 (46)	269 (44)	
Area of residence							0.036
Rural	17 (63)	232 (84)	249 (82)	19 (76)	517 (88)	536 (88)	
Urban	10 (37)	43 (16)	53 (18)	6 (24)	70 (12)	76 (12)	
Education							<0.001
None	4 (15)	118 (43)	122 (40)	5 (20)	306 (52)	311 (51)	
Class 1-4	8 (30)	72 (26)	80 (27)	3 (12)	61 (10)	64 (11)	
Class 5-9	9 (33)	55 (20)	64 (21)	16 (64)	160 (27)	176 (29)	
Class 10 or more	6 (22)	30 (11)	36 (12)	1 (4)	49 (8)	50 (8)	
Unknown	0	0	0	0	11 (2)	11 (2)	
Duration of jaundice at	the time of c	leath					0.002
≤ 1 month	21 (78)	197 (72)	218 (72)	16 (64)	356 (61)	372 (61)	
1< and ≤ 2 months	5 (19)	49 (18)	54 (18)	1 (4)	138 (24)	139 (23)	
> 2 and \leq 3 months	1 (4)	29 (11)	30 (10)	8 (32)	93 (16)	101 (17)	
Sought care from a qua	lified health	care provider	¥				
First visit	-	-	-	15 (60)	343	358 (59)	
First or second visit	-	-	-	20 (80)	481	501 (82)	
Any visit	-	-	-	21 (84)	544	565 (92)	
Place of death							0.103
Health facility	14 (52)	51 (19)	65 (22)	15 (60)	85	100 (16)	
Home	13 (48)	224 (81)	237 (78)	7 (28)	480	487 (80)	
In-transit				3 (12)	22	25 (4)	

453 * Among persons aged \geq 14 years 454

+ Chi-squared test comparing total deaths in hospitals and hospital catchment areas by patients' characteristics

455 ¥ Health facility/qualified medical doctor/paramedic/nurse

456 Table 4: Estimation of HEV associated mortality in the catchment areas of six acute jaundice 457 surveillance hospitals in Bangladesh, 2014

Mortality estimation (indicators)	Ν
Estimated population and live births in the hospital catchment areas (projected for 2014; Appendix 1)	
Population aged \geq 14 years [P]	1,595,697
Live births [B]	52,326
Surveillance hospitals	
Maternal deaths	
Maternal deaths with acute jaundice $[J_m]$	27
HEV cases among maternal deaths with acute jaundice $[E_m]$ (95% CI)	8 (4-13)
Non-maternal deaths	
Non-maternal deaths with acute jaundice [J]	275
HEV cases among non-maternal deaths with acute jaundice [$\varSigma E_i$] (95% CI)	20 (13-30)
Stillbirths	
Stillbirths delivered by mothers with acute jaundice $[S_j]$	27
Stillbirths delivered by HEV positive mothers [S_e] (95% CI)	6 (3-11)
Neonatal deaths	
Neonatal deaths born to mothers with acute jaundice $[N_j]$	15
Neonatal death cases born to HEV positive mothers [N_e] (95% CI)	10 (6-13)
Hospital catchment areas	
Maternal deaths with acute jaundice $[D_m]$ (95% CI)	25 (16-37)
Non-maternal deaths with acute jaundice [D] (95% CI)	587 (401-772)
¹ Expected number of non-maternal HEV deaths $\sum D_i \frac{E_i}{I_i}$	37
Stillbirths delivered by mothers with acute jaundice [S] (95% CI)	57 (43-74)
Neonatal deaths delivered by mothers with acute jaundice [N] (95% CI)	53 (40-69)
HEV associated mortality	
HEV associated mortality per 100,000 population aged ≥ 14 years (95% CI)	0.93 (0.6-1.3)
Maternal mortality ratio due to HEV per 100,000 live-births (95% CI)	4.7 (1.6-11.4)
Stillbirth rate due to HEV per 100,000 live-births (95% CI)	8.1 (2.9-19.2)
Neonatal mortality rate due to HEV per 100,000 live-births (95% CI)	22.5 (10.5-37.5)

458 ¹The expected number of non-maternal HEV-associated deaths for a specific age group in the hospital catchment areas was 459 calculated by multiplying the number of non-maternal jaundice-associated deaths in the hospital catchment areas by the 460 proportion of HEV-associated cases among non-maternal jaundice-associated deaths in the surveillance hospitals for that age 461 group. For instance, for the 15-44 age group, there were 158 jaundice-associated non-maternal deaths in the catchment areas 462 (Table 3), and the proportion of HEV-associated deaths among non-maternal deaths in that age-group in the surveillance 463 hospitals was 14.6% (Table 3), yielding an expected number of HEV-associated deaths in the catchment areas of 23.07 (i.e., 158 x

464 0.146).